Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05238649

Recruitment Status : Active, not recruiting

First Posted : February 14, 2022

Last Update Posted : March 29, 2022

Sponsor:

Information provided by (Responsible Party):

Livzon Pharmaceutical Group Inc.

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	November 30, 2022
Estimated Study Completion Date :	January 28, 2023

To Top